Follow
Wee Loong Chin
Title
Cited by
Cited by
Year
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
RM Zemek, E De Jong, WL Chin, IS Schuster, VS Fear, TH Casey, ...
Science translational medicine 11 (501), eaav7816, 2019
1872019
Sensitizing the tumor microenvironment to immune checkpoint therapy
RM Zemek, WL Chin, AK Nowak, MJ Millward, RA Lake, WJ Lesterhuis
Frontiers in immunology 11, 223, 2020
632020
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice
RM Zemek, WL Chin, VS Fear, B Wylie, TH Casey, C Forbes, CM Tilsed, ...
Nature Communications 13 (1), 4895, 2022
212022
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma
WS Lam, J Creaney, FK Chen, WL Chin, S Muruganandan, ...
Lung Cancer 140, 87-92, 2020
212020
Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
SJ Dart, AM Cook, MJ Millward, AM McDonnell, WL Chin, MU Hakeem, ...
Scientific Reports 11 (1), 15312, 2021
172021
Characterising the binding specificities of the subunits associated with the KMT2/Set1 histone lysine methyltransferase
BL Murton, WL Chin, CP Ponting, LS Itzhaki
Journal of molecular biology 398 (4), 481-488, 2010
172010
CD4+ T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy
CM Tilsed, N Principe, J Kidman, WL Chin, MLO Morales, RM Zemek, ...
Cell Reports 41 (13), 2022
72022
Immune checkpoint inhibitor therapy for malignant pleural mesothelioma
AK Nowak, WL Chin, S Keam, A Cook
Lung Cancer 162, 162-168, 2021
72021
Comprehensive testing of chemotherapy and immune checkpoint blockade in preclinical cancer models identifies additive combinations
N Principe, WJ Aston, DE Hope, CM Tilsed, SA Fisher, L Boon, IM Dick, ...
Frontiers in immunology 13, 872295, 2022
52022
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med
RM Zemek, E De Jong, WL Chin, IS Schuster, VS Fear, TH Casey, ...
52019
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci. Transl. Med. 11, eaav7816
RM Zemek, E De Jong, WL Chin, IS Schuster, VS Fear, TH Casey, ...
52019
Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery
WL Chin, RM Zemek, WJ Lesterhuis, T Lassmann
Molecular Systems Design & Engineering 4 (4), 689-700, 2019
52019
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma–a phase II randomised trial
VD Haakensen, ÅK Öjlert, S Thunold, S Farooqi, AK Nowak, WL Chin, ...
European Journal of Cancer, 113973, 2024
12024
LBA99 First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line …
A Helland, VD Haakensen, AK Ojlert, SMH Thunold, AK Nowak, WL Chin, ...
Annals of Oncology 34, S1337, 2023
12023
Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy
WL Chin, RM Zemek, CM Tilsed, ARR Forrest, VS Fear, C Forbes, L Boon, ...
Scientific Data 11 (1), 448, 2024
2024
Spectral detection of condition-specific biological pathways in single-cell gene expression data
WL Chin, LP dos Santos, M Small, WJ Lesterhuis, T Lassmann
bioRxiv, 2023.03. 12.532317, 2023
2023
Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy
R Zemek, WL Chin, V Fear, B Wylie, T Casey, C Forbes, C Tilsed, L Boon, ...
2021
A bioinformatics approach to biomarker validation using publically available RNAseq data from immunotherapy trials
WL Chin, R Zemek, RA Lake, AK Nowak, T Lassmann, W Lesterhuis
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 14, 145-146, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–18